The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
Email enquiries
If you have any queries please email Scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 November 2025 | Following discussions with the company, the evaluation of concizumab has been split into 2 indications. Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors will continue as ID5099. Concizumab for treating haemophilia A or B in people 12 years and over with inhibitors will progress under a new ID number, ID6665. |
| 14 November 2025 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 05 May 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual